Moderna
Moderna Slashes 2025 Revenue Forecast, Expands Cost-Cutting Measures Amid Vaccine Sales Decline
Moderna, 2025 revenue forecast, cost-cutting measures, vaccine sales decline, COVID-19 vaccine market competition, falling vaccination rates.
Moderna Co-Founder Kenneth Chien’s New Biotech Secures $950M RNA Deal with Etherna
Kenneth Chien, Moderna, Etherna, RNA deal, biotech, mRNA therapies
Moderna CEO Reflects on 2024 Challenges and Advances in Shareholder Letter
Moderna, shareholder letter, 2024 review, RSV vaccine, COVID-19 vaccine, mRNA medicines, Stéphane Bancel
Moderna’s RSV Vaccines Face Safety Concerns Over Severe Infections in Infants
Moderna, RSV vaccines, safety concerns, severe infections, infants, mRNA vaccines, FDA, advisory committee
Moderna’s COVID-19 Vaccine Sales Exceed Expectations, but RSV Vaccine Falls Short
Moderna, COVID-19 vaccine, RSV vaccine, vaccine sales, pharmaceutical industry
Moderna Faces Second Consecutive Marketing Breach for Spikevax Vaccine
Moderna, Spikevax, Marketing Breach, COVID-19 Vaccine, Regulatory Compliance
Moderna Revamps R&D Strategy with $1.1B Cuts and Pipeline Overhaul
Moderna, R&D cuts, pipeline overhaul, biotechnology, pharmaceutical industry, cost reduction, research and development.
GSK Abandons HSV Vaccine Development After Phase 2 Failure, Paving Way for Moderna and BioNTech
GSK, HSV vaccine, phase 2 failure, Moderna, BioNTech, mRNA vaccines, herpes simplex virus
Moderna’s Mpox Vaccine Shows Superior Efficacy in Preclinical Study Compared to Approved Version
Moderna, Mpox vaccine, Preclinical study, Superior efficacy, Approved version
FDA Approves Updated COVID-19 Vaccines from Pfizer and Moderna for Enhanced Protection
COVID-19 vaccines, FDA approval, mRNA vaccines, Pfizer, Moderna, updated vaccines, KP.2 variant, JN.1 lineage, emergency use authorization, vaccination guidelines.